FHAM
NKTR icon

Folger Hill Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Folger Hill Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,281
Closed -$451K – 330
2017
Q1 		$451K Buy
+1,281
New +$288K 0.04% 241

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Folger Hill Asset Management's NKTR Position: Q2 2017 in Review

Folger Hill Asset Management sold out of Nektar Therapeutics (NKTR) in Q2 2017, closing a stake of 1,281 shares — an estimated $451K sold.

Folger Hill Asset Management first reported a position in NKTR in Q1 2017 and held it in 1 quarter. The position peaked at $451K in Q1 2017. 197 funds tracked by Wall St. Rank hold NKTR as of Q2 2017.

  • Folger Hill Asset Management reported no remaining Nektar Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Folger Hill Asset Management sold 1,281 Nektar Therapeutics shares in Q2 2017, an estimated $451K.
  • Folger Hill Asset Management first reported a position in Nektar Therapeutics in Q1 2017 and held it in 1 quarter.
  • Folger Hill Asset Management's Nektar Therapeutics position peaked at $451K in Q1 2017.
  • 197 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2017.

Based on Folger Hill Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.